Sun Pharma’s $4B Ranbaxy Buy Brings Consumer Products Business With New Growth Focus
This article was originally published in The Tan Sheet
Executive Summary
In a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to sustain growth momentum.
You may also be interested in...
Pfizer Expects OTC Nexium Will Launch With Market Exclusivity
Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.